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Abstract
Background: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients,
but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and
osteoblasts, which form hematopoietic stem cell niches, and therefore may affect hematopoietic cells that play a
role in breast cancer progression.
Method: Immunocompetent and immunocompromised strains of mice commonly used for breast cancer research were
injected with a single, clinically relevant dose of ZOL (100 μg/kg) or vehicle control. The effects of ZOL on the
bone marrow microenvironment (bone volume, bone cell number/activity, extracellular matrix composition)
were established at various time points following treatment, using micro-computed tomography (μCT) analysis,
histomorphometry, ELISA and immunofluorescence. The effects on peripheral blood and bone marrow hematopoietic
progenitor populations were assessed using a HEMAVET® hematology analyzer and multicolor flow cytometry,
respectively. Tumor support function of bone marrow cells was determined using an in vivo functional assay
developed in our laboratory.
Results: Using multiple mouse strains, we observed transient changes in numbers of hematopoietic stem cells,
myeloid-biased progenitor cells, and lymphoid-biased cells concurrent with changes to hematopoietic stem cell
niches following ZOL administration. Importantly, bone marrow cells from mice treated with a single, clinically relevant
dose of ZOL inhibited breast tumor outgrowth in vivo. The ZOL-induced tumor suppressive function of the bone marrow
persisted beyond the time point at which numbers of hematopoietic progenitor cells had returned to baseline.
Conclusions: These findings provide novel evidence that alterations to the bone marrow play a role in the anti-tumor
activity of ZOL and suggest possibilities for capitalizing on the beneficial effects of ZOL in reducing breast
cancer development and progression.
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Background
Breast cancer patients who have bone metastases experi-
ence significant morbidity due to the osteolytic nature of
the disease [1]. Bisphosphonates inhibit osteoclast activity
and are used to treat patients with bone metastases and/or
osteoporosis. Recent clinical results showed that women
treated with bisphosphonates, including zoledronic acid
(ZOL), are at reduced risk of breast cancer development
and recurrence [2, 3]. Nevertheless, how ZOL exerts its
protective effect is not fully understood.
Breast cancer development and progression involves
not only dissemination of tumor cells to the bone but
also the recruitment of tumor-supportive hematopoietic
progenitor cells from the bone marrow [4], thus opening
the possibility of targeting these cell populations as part
of anti-cancer therapy. It is therefore important to estab-
lish how bone-targeting agents, widely used to treat osteo-
porosis and breast cancer-induced bone disease, modify
progenitor cell populations in the bone marrow.
Within bone, specialized cellular niches sustain
hematopoiesis by providing molecular cues that regulate
hematopoietic stem cell (HSC) quiescence, proliferation,
differentiation and mobilization [5–7]. Under normal
physiological conditions, quiescent HSCs reside in less
perfused endosteal niches and in greater proximity to
osteoblastic cells than actively proliferating HSCs, which
are commonly juxtaposed with sinusoidal endothelium and
endothelial cells in vascular niches [8, 9]. Given that endos-
teal and vascular niche components are critical for main-
taining hematopoietic homeostasis, it is not surprising that
modulation of either of these niches impacts hematopoietic
cells, particularly HSCs [10–12]. For example, it is well-
established that an elevation in osteoblast numbers results
in an increase in HSCs within the bone marrow [10, 13],
whereas depletion of cells with osteoblastic differentiation
potential decreases the numbers of HSCs [14].
The nitrogen-containing bisphosphonate, ZOL, inhibits
enzymes in the mevalonate pathway, thus inducing osteo-
clast apoptosis and resulting in inhibition of bone resorp-
tion [15, 16]. Various in vitro and in vivo studies have
identified osteoclasts and monocyte/macrophages as the
primary targets of bisphosphonates, due to their high
endocytic capacity [16–20]. Emerging evidence supports
the theory that ZOL targets additional cell types in bone,
including osteoblasts [21] and vascular endothelial cells
[22], although whether these effects are direct or indirect,
and their impact on hematopoiesis and disseminated
tumor cells, remains unclear.
Here we report that a clinically relevant dose of ZOL
has significant and transient effects on hematopoiesis in
the bone marrow in vivo, concomitant with changes to
the endosteal and vascular niches. Importantly, we
demonstrate that a single administration of ZOL generates
tumor-suppressive bone marrow cells that are capable of
inhibiting breast tumor outgrowth when transplanted into
new hosts. Our findings provide novel evidence that
ZOL-mediated alterations to the bone marrow may play
a role in the anti-tumor activity of ZOL observed in
breast cancer clinical trials.
Methods
Mice
Experiments were performed in 6 to 7-week-old female
NCr-Nu (nude), CrTac:NCr-Foxn1nu mice (Taconic
Laboratories, Hudson, NY, USA) and 6 to 7-week-old
female C57BL/6 mice (The Jackson Laboratory, Bar
Harbor, ME, USA). All procedures were performed in
accordance with the regulations of Boston Children’s
Hospital Institutional Animal Care and Use Committee
(protocol 12-11-2308R).
Zoledronic acid administration
ZOL [1-hydroxy-2-(1H-imidazole-1-yl)ethylidene-bispho-
sphonic acid] (Zometa, Novartis Pharmaceuticals,
Cambridge, MA, USA) was diluted to a working con-
centration of 4 mg/mL in 1X Hank’s Balanced Buffer
Solution (HBBS, Gibco, 14065-056) and stored at 4 °C
until use. A single dose of 100 μL of 1X HBBS or
100 μg/kg ZOL was administered to mice via intraper-
itoneal (i.p.) injection.
Bone marrow, spleen and blood preparation
Femora and tibiae were dissected free into 2% FBS in PBS.
Bone marrow cells (BMCs) were collected by centrifuga-
tion of mouse femora and tibiae at 6000–7000 g for 4 mi-
nutes at 4 °C. Cells were then incubated with red blood
cell (RBC) lysis solution (BioLegend 420301) for 5 minutes
on ice, washed once with BMC buffer, re-suspended in
0.5 mL of sterile BMC buffer, and passed through a 5-mL
polystyrene round-bottom tube with a cell-strainer cap
(Corning, 352235). One fourth of the spleen was mechan-
ically dissociated with a razor blade, incubated with RBC
lysis solution (BioLegend 420301) for 5 minutes on ice,
washed once with PBS, and filtered through a 70-μM
nylon mesh filter. Next, 200 μL of peripheral blood was
incubated with RBC lysis solution (BioLegend 420301) for
10 minutes at room temperature, washed once with PBS
passed through a 5-mL polystyrene round-bottom tube
with a cell-strainer cap (Corning, 352235). At the experi-
mental end points, blood was collected by intracardiac
puncture with a 27-gauge needle into ethylenediaminetet-
raacetic acid (EDTA) Microtainer tubes (BD Pharmin-
gen). Complete blood counts were obtained using a
HEMAVET® hematology analyzer (Drew Scientific). Plasma
was prepared by centrifugation of whole blood at 1500 g
for 8 minutes at 4 °C.
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Flow cytometry
BMCs (preparation as previously described) were in-
cubated with appropriate antibodies for 30 minutes
at 4 °C. Dead cells were eliminated from analysis
using 7-aminoactinomycin D (7-AAD; BioLegend),
and flow cytometry gating was used to exclude debris and
cell clumps. Countbright Absolute counting beads (Life
Technologies, C36950) were added to the samples to
quantify the numbers of cells of any given lineage and
report absolute differences between cohorts. Data
were acquired on a Canto II or a FACSAria IIu/FACS-
Diva (BD Biosciences). Data analyses were performed
using FlowJo software (TreeStar). Antibody informa-
tion, dilutions, and cell gating strategies are included
in Additional file 1: Table S1, Additional file 2: Table
S2 and Additional file 3: Figure S1.
Bromodeoxyuridine (BrdU) incorporation
BrdU incorporation was performed per manufacturer’s
instructions using the BD Pharmigen APC BrdU Flow
Kit (Catalog number 552598). Mice were injected i.p.
with 100 μL of 1 mg BrdU solution 2 hours prior to
tissue harvest. BMCs (preparation as previously described)
and cell-surface antigens were stained using the antibodies
indicated in Additional file 1: Table S1. Cells were fixed
and permeabilized with BD Cytofix/Cytoperm Buffer and
treated with 100 μL of 300 μg/mL DNase to expose incor-
porated BrdU prior to staining with APC BrdU antibody
(BD Biosciences, 557892).
Cell colony assays
BMCs, spleen cells, and peripheral blood cells (preparation
as previously described) were passed through a 70-μM
nylon mesh filter. BMCs (3 × 104) were prepared and plated
into 35-mm Petri dishes in Mouse Colony-Forming Unit
(CFU) Methocult™ Assays (Stemcell Technologies Inc.,
M3434) according to the manufacturer’s instructions.
Colonies were counted after 10 days of culture.
Ki67 immunohistochemistry and quantification
Femora were dissected free and fixed in 4% (wt/vol)
paraformaldehyde (PFA) for 24 hours, stored in 70%
ethanol for 24 hours, embedded in paraffin, and sec-
tioned onto ProbeOn Plus slides (Fisher Scientific).
Tibiae were dissected free and fixed in ice cold 4%
PFA (pH 7.4 in PBS) for 48–72 hours and decalcified
in 0.5 M EDTA/0.5% PFA (pH8, in PBS) for 2 weeks
at 4 °C followed by paraffin embedding. Proliferating
BMCs were identified by staining with an antibody
to Ki67 (Abcam, catalog number ab15580, dilution
1:200) and a secondary Vectastain kit (ABC, Rabbit IGG,
PK-6101) with AEC Chromogen Substrate (Dako, K3461).
Tissues were counter stained with hematoxylin (Vector la-
boratories, VWR101098-062). Images were captured
with identical exposure and gain for any given experiment,
using a Nikon Eclipse Ni microscope. Staining was quanti-
fied using ImageJ (NIH) and CellProfiler (The Broad Insti-
tute) image analysis software.
Osteoclast (TRAP) and osteoblast quantifications
Osteoblast and osteoclast number/mm trabecular bone was
quantified on H&E or tartrate-resistant acid phosphatase
(TRAP)-stained sections of tibiae covering all trabecular
bone surfaces 200 μm away from the epiphysis, as described
previously [21]. Osteoblasts were identified by their large
Golgi complex, single, distinct nucleus, cuboidal shape and
proximity to endosteal surfaces. Osteoclasts were identified
by their bright pink appearance after TRAP staining. Two
non-serial 3-μm-thick sections were assessed per sample
using an Olympus BX53 (×20 objective) and OsteoMeasure
software (Osteometrics). Detailed scoring methodologies are
illustrated in Additional file 4: Figure S2A.
Extracellular matrix deposition
Proteoglycan-rich extracellular matrix in the epiphysis
and metaphysis were visualized by toluidine blue staining
on sections of tibiae. Two non-serial 3-μm-thick sections
were assessed per sample using an Olympus BX53 a Leica
DMRB microscope (×2.5 objective) and the area of
interest (AOI) within a total tissue area of 1 mm2 was
calculated using OsteoMeasure software (Osteometrics;
see Additional file 4: Figure S2B). Cortical and trabecular
bone surfaces not directly connected to the dense network
of trabeculi at the epiphysis were excluded from analysis.
Micro-computed tomography (μCT) analysis
The trabecular bone volume of femora was analyzed using
a SkyScan 1272 device (SkyScan). Femora were scanned
using 200 mA, 51 kV, a 0.5-mm aluminum filter, medium
camera resolution of 2016 × 1344 and pixel size set to
4.3 μm. Images were reconstructed using NRecon soft-
ware and a bone volume of interest (VOI) was determined
by interactively drawing on the two-dimensional images.
Analysis was started from a fixed offset 0.7 mm away from
the proximal end of the growth plate covering a length of
1.5 mm. Grayscale images of the VOI were converted into
binary images (threshold 95 − 225) and bone parameters
were calculated using the CTAn software.
Visualization of bone marrow vasculature
Tibiae were fixed in ice cold 4% PFA (pH 7.4, in PBS)
for 4 hours at 4 °C, decalcified in 0.5 M EDTA (pH 8, in
PBS) for at least 24 hours, transferred to 20% sucrose/2%
polyvinylpyrrolidone (PVP) solution (in PBS) over-
night at 4 °C followed by embedding in 8% gelatine/
20% sucrose/2% PVP and 30-μm-thick sections were
prepared using a cryostat at -20 °C as described by
Kusumbe et al. 2014 [23].
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Bone marrow vasculature was visualized by immuno-
fluorescent staining using antibodies against the vascular
endothelial cell marker Endomucin (1:100, Endomucin
V.7C7, rat monoclonal, Santa Cruz, sc-65495) and CD31
(1:100, DIA-310: Anti-CD31 (Ms) from Rat (Clone: SZ31)).
Alexa Fluor 555, goat anti-rat IgG, (LifeTechnologies,
A21434 (1:200)) was used as the secondary antibody.
Images were acquired using a Nikon A1 confocal micro-
scope, NIS-Elements-software Version 4.30, CFI Plan Fluor
20x MI (NA 0.75) or a Nikon inverted Ti eclipse, NIS-
Elements software Version 4.30, Plan Apo 20x (NA 0.75).
For a subset of samples, Z-stacks of 20-μm depth (0.9-μm
intervals, 23 steps) were acquired and 3D projections
reconstructed using Fiji (ImageJ, Version 2.0.0-rc-24/1.49 m,
Image > Stacks > 3D projections). Brightness and contrast
for the entire images were adjusted using Fiji or NIS-
Elements-software. The Nikon Eclipse Ti microscope
was used to produce tile scans (8 × 8). Aperio Image-
Scope software was used to track vessels positively
stained for endomucin in an average area of bone marrow
of 615 x 1095 μm from the top of the growth plate.
Cells
Human breast cancer MDA-MB-231 BO2F11 luciferase-
transfected bone-tropic cells were a kind gift from the
van der Pluijm laboratory (Leiden University Medical
Center, The Netherlands) [24]. Cells tested negative for
mycoplasma and were validated by short tandem repeat
(STR) profiling by the Molecular Diagnostics Laboratory
at the Dana-Farber Cancer Institute.
Bioluminescent imaging
Mice were anesthetized with 2.5% isoflurane and injected
i.p. with 150 mg/kg D-luciferin (Perkin-Elmer). Luciferase-
positive cells were detected using a Xenogen IVIS imaging
system (Caliper Life Sciences) 10 minutes after luciferin
injection. Luminescence signal was detected for the regions
of interest as radiance (p/sec/cm2/sr) and analyzed
using the Living Image Software Version 4.1 (Caliper
Life Sciences).
Bone marrow functional analysis and subcutaneous
tumor growth
BMCs were freshly harvested from cohorts of donor
mice (preparation as described previously) and immedi-
ately admixed with MDA-MB-231 BO2F11 tumor cells in
DMEM with 10% Matrigel (BD, Growth Factor Reduced,
356230). For each injection, 750,000 BMCs from a given
donor mouse were admixed with 250,000 tumor cells in
100 μL DMEM/10% Matrigel. BMCs from each donor
mouse were distributed bilaterally into three recipient
nude mice, with six possible tumors per donor. Tumor
growth was monitored by in vivo imaging system (IVIS)
imaging of all mice and caliper measurements were
taken for all palpable tumors. Volume was estimated as
0.5 × length × width2.
Statistical analysis
All data were analyzed with the use of GraphPad Prism
Software (Version 6). Data are expressed as mean ± SEM.
Results were analyzed using Student’s t test, unless other-
wise indicated, and were considered statistically significant
if the p value was ≤0.05.
Results
Effect of zoledronic acid on hematopoietic stem and
progenitor cells
To determine whether ZOL impacts hematopoiesis, we
used two different strains of mice - nude and C57BL/6 -
that are commonly used in breast cancer research. While
patients with osteoporosis or metastatic bone disease are
often treated for chronic disease [25], our goal was to
evaluate the effects of ZOL on hematopoiesis in the
absence of overt bone disease. We also reasoned that
effects on hematopoiesis should be analyzed over a time
period when ZOL is known to be bioavailable in the
bone. ZOL is known to concentrate in the bone within
24 hours of administration and is cleared during bone
turnover, which occurs at a rate of around 0.7% per day
in the mouse and thus, takes 2 weeks to complete [26].
Hence, we administered a single, clinically relevant dose
of 100 μg/kg ZOL (comparable to the 4-mg clinical dose
that has been well-established to inhibit osteoclast activity
in vivo [21]) to cohorts of immunocompromised (nude)
and immunocompetent (C57BL/6) mice and analyzed
hematopoietic cells at various time points over a course
of 2 weeks (Fig. 1a).
In the nude mice, the numbers of HSCs (LSK/
CD150+/CD48-/CD34-/Flt3-) in the marrow of ZOL-
treated mice were elevated 1.8-fold (p = 0.003) relative to
the control cohort 3 days after administration, after which
the numbers returned to baseline (Fig. 1b, Table 1). In
agreement with these results, numbers of both short-term
HSCs (ST-HSCs, LSK Flt3+ CD34-) and long-term HSCs
(LT-HSCs, LSK Flt3- CD34-) were elevated 4.1-fold (p =
0.01) and 4.8-fold (p = 0.06), respectively (Table 1).
Similar results were observed in C57BL/6 mice; how-
ever, the maximal effect on HSC populations occurred
2 days later than in the nude mice. Specifically, no dif-
ferences were observed between the control and the
ZOL-treated cohorts 3 days after administration, while
at the 5-day time point, there was a 1.8-fold increase in
HSCs (p = 0.04), a 2.0-fold increase in LT-HSCs (p =
0.03), and a 1.7-fold increase in ST-HSCs (p = 0.05),
after which these numbers returned to baseline and
remained stable until the experimental end point at day
20 (Fig. 1g, Table 1).
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Fig. 1 (See legend on next page.)
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To determine whether increased cell proliferation could
account for the observed changes in HSCs numbers, we
injected ZOL-treated and vehicle-treated mice with BrdU
and analyzed HSCs by flow cytometry. The BrdU+ HSCs
as a percentage of total HSCs were not significantly differ-
ent between the ZOL-treated and control-treated cohorts
at any time point analyzed, even at time points as early as
24 and 48 hours after ZOL treatment (Fig. 1c, Additional
file 5: Figure S3d). These data suggest that while ZOL
treatment results in a significant expansion of HSCs in the
marrow, the percentage of proliferating cells is constant
and therefore, the increase in numbers of HSCs is likely
due to differences in their proliferation rates rather than
to HSCs amassing in a quiescence phase.
Given that the HSC numbers were significantly elevated
at 3 days (nude mice) and 5 days (C57BL/6 mice) after
ZOL treatment, we focused on these time points to deter-
mine if ZOL was increasing the numbers of functional
HSCs. To do so, we performed CFU assays using BMCs
isolated from both vehicle-treated and ZOL-treated mice
Table 1 Zoledronic acid-induced modifications to bone marrow hematopoietic and progenitor cell numbers over time
Average numbers of indicated bone marrow HPC populations (number of cells ± SEM) from nude and C57BL/6 mice as determined by flow cytometry on one
femur per mouse at indicated time points following control (CTL) or one 100 μg/kg dose of zoledronic acid (ZOL) treatment; n = 15; N= 5 mice per group × three
biological replications. Dark yellow shaded boxes represent statistical significance relative to CTL; p values indicated. d. day, LT-HSCs long-term HSCs, ST-HSCs short-term
HSCs, LSKs Lin-Sca1+cKit+, MPPs multipotent progenitor populations, CMPs common myeloid progenitors, MEPs megakaryocyte/erythroid progenitors, GMPs gran-
ulocyte/monocyte progenitors, LBPs lymphoid-biased progenitors, CLPs common lymphoid progenitors
(See figure on previous page.)
Fig. 1 Impact of zoledronic acid (ZOL) on hematopoietic and peripheral blood cells. a Cohorts of C57BL/6 and nude mice (n = 5 per cohort per
experiment × three experiments) were administered a single 100-μg/kg dose of ZOL or vehicle control (100 μl Hanks Balanced Salt Solution
(HBSS)) via intraperitoneal injection and tissues were analyzed at indicated time points (red arrows) (b-d, f, g). b Number of hematopoietic stem
cells (HSCs) per nude or C57BL/6 mouse femur at indicated time points after ZOL treatment, determined by flow cytometry using counting beads;
**p = 0.003,*p = 0.04 (n = 15; 5 mice per cohort for each of three biological replications). c Bromodeoxyuridine (BrDU)-positive HSCs as a percent-
age of total HSCs per nude or C57BL/6 mouse femur; n.s. not significant; n = 10 femora (five mice, two femora per mouse). d Colony forming unit
(CFU) assays using bone marrow cells (BMCs) isolated from both vehicle and ZOL-treated mice 3 (nude mice) or 5 days (C57BL/6 mice) after ZOL
treatment. Colonies were counted 10 days later; nude mice *p = 0.04, C57BL/6 mice *p = 0.05. e BMCs from three naïve C57BL/6 mice and three
nude mice were prepared in triplicate and subjected to CFU assay in the presence of 10 μM ZOL or 10 μL of 1X HBBS; colonies were counted
after 10 days; n.s. not significant. f Representative Ki67 immunohistochemical stains of bone marrow from vehicle and ZOL-treated mice 5 days
(C57BL/6) or 3 days (nude mice) after treatment (×40 objective). Quantification of Ki67 staining from indicated mice and time points. Colors indi-
cate different biological replications; each data point represents an individual mouse for which an average of three different fields of view was cal-
culated; nude mice *p < 0.0001, C57BL/6 mice **p = 0.0007. g Average fold change in bone marrow hematopoietic progenitor populations (HPCs)
(quantified from one femur per mouse by flow cytometry; n = 5, representative of three biological replications) at indicated time points after one
100 μg/kg ZOL dose as compared to vehicle treatment. Ctl control, LT-HSCs long-term HSCs, ST-HSCs short-term HSCs, LSKs Lin-Sca1+cKit+, MPPs multi-
potent progenitor populations, CMPs common myeloid progenitors, MEPs megakaryocyte/erythroid progenitors, GMPs granulocyte/monocyte progeni-
tors, LBPs lymphoid-biased progenitors, CLPs common lymphoid progenitors. Also see Table 1
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at these time points. We found that ZOL significantly in-
creased the number of CFUs in both strains of mice (nude
mice, day 3: control 5.2 ± 1.4, ZOL 10.4 ± 1.6, p = 0.04;
C57BL/6 mice, day 5: control 11.6 ± 4.0, ZOL 21.6 ± 5.7,
p = 0.05) (Fig. 1d). Additionally, no increases in the
number of CFUs were observed in the spleen or peripheral
blood 3 days after ZOL administration as compared to con-
trol treatment, indicating that the effect of ZOL was specific
to the bone marrow (Additional file 5: Figure S3c).
To determine whether the increased HSC function
could be ascribed to direct effects of ZOL on HSCs, we
isolated BMCs from naïve mice and subjected them to
the CFU assay in the presence of either vehicle or 10 μM
ZOL in vitro (a dose comparable to the 100 μg/kg dose
used in vivo). Ten days after treatment, no differences in
the number of CFUs between the groups were observed
(Fig. 1e), suggesting that ZOL did not act directly on
HSCs to mediate their expansion in vivo and that this
expansion was not attributed to direct drug storage and
release from the bone matrix.
We next determined whether ZOL affected the prolifer-
ation of other bone marrow hematopoietic cells. To start,
we stained sections of tibiae with an antibody specific for
the proliferation marker Ki67. The numbers of Ki67+ cells
per field in the marrow of ZOL-treated nude mice were
increased by around 82% (p < 0.0001) and in C57BL/6
mice by around 74% (p = 0.0007), compared to the re-
spective vehicle controls (Fig. 1f). These results prompted
us to carry out a more detailed analysis of the specific
hematopoietic progenitor cell (HPC) populations at vari-
ous time points after administration of control treatment
or ZOL, using flow cytometric analysis (Additional file 1:
Table S1, Additional file 2: Table S2 and Additional file 3:
Figure S1).
Compared to control treatment, ZOL had significant
effects on a number of BMC populations in the nude
mice (Table 1, Fig. 1g). Specifically, there was a 1.3-fold
increase in the Lin-Sca1+cKit+ (LSK) populations (p =
0.02) accompanied by a non-significant 1.8-fold increase
in multipotent progenitors (MPPs, LSK/CD150-/CD48+)
3 days after ZOL-treatment (p = 0.1). Common myeloid
progenitor cell (CMP, Lin-Sca1-cKit+IL7Ra-CD34 + FcγRII/
III-) numbers were elevated 2.0-fold (p = 0.03) and 3.4-fold
(p = 0.01) at the 3-day and 5-day time points, respectively.
Megakaryocyte-erythroid progenitors (MEPs, Lin-Sca1-
cKit + IL7Ra-FCγRII/II-CD34-) were elevated 1.8-fold
(p = 0.03) on day 5. Numbers of granulocyte-macrophage
progenitors (GMPs, Lin-Sca1-cKit + IL7R-CD34 + FcγRII/
III+) appeared to be elevated 5 days after ZOL treatment
compared to the control cohort, although this change was
not statistically significant (1.4-fold increase, p = 0.2).
Common lymphoid progenitors (CLPs, Lin-/scaint/ckitin-
tILRa+), which are present in nude mice, were decreased
1.5-fold (p = 0.04) at the 5-day time point in the marrow
of ZOL-treated mice. In all cases, the numbers of these
various progenitor cells returned to baseline by day 10.
In the C57BL/6 mice, the changes in HPC numbers
followed some of the same trends as those observed in
the nude mice, although with different kinetics (Fig. 1g,
Table 1). The numbers of MPPs were increased 1.4-fold
by day 5 (p = 0.004) and 1.3-fold by day 10 (p < 0.0001).
CMPs and MEPs were elevated 1.5-fold (p = 0.1) and
1.6-fold (p = 0.07), respectively, after 15 days, although
these numbers were not statistically significant. GMPs
were significantly elevated 1.3-fold (p = 0.02) at the 15-day
time point in the marrow of ZOL-treated mice. In all cases,
the numbers of these various progenitor cells returned to
baseline by day 20. Additionally, we observed a significant
2.2-fold (p = 0.0003) decrease in the number lymphoid
biased progenitor (LBP) populations in the C57BL/6 mice
5 days after ZOL treatment, after which these numbers
were not statistically different from those in the control
cohort. In these C57BL/6 mice, we also observed signifi-
cant 3.1-fold (p = 0.0001) and 2.5-fold (p = 0.003) increases
in the number of common lymphoid progenitor (CLP)
populations 5 and 10 days after ZOL treatment, respect-
ively. The decrease in LBPs and increase in CLPs indicate
that it is possible that the effect of ZOL on the bone
marrow drives LBPs toward differentiation into the
downstream CLP populations.
Collectively, these results established that ZOL has pro-
found and transient effects on hematopoiesis in both nude
and C57BL/6 mice. In particular, the effects of ZOL ap-
peared to favor differentiation toward common lymphoid
progenitors and expansion of myeloid lineage progenitors,
which may be accounted for by the significant expansion
in HSCs. Additionally, our results suggest that the effects
of ZOL on HSC proliferation and expansion are indirect.
Effect of zoledronic acid on peripheral blood monocytes
and neutrophils
A number of reports have demonstrated that bisphospho-
nate treatment reduces circulating monocytes and neutro-
phils [27, 28]. It is also well-established that hematopoiesis
in the marrow compensates for significant alterations
in circulating blood cell numbers [29]. Hence, we next
investigated how the changes to hematopoietic cells in
the marrow related to peripheral blood counts during the
approximate 2-week time period after ZOL administration.
We analyzed circulating blood cell populations at
various time points after ZOL or control treatment in
both strains of mice. In the C57BL/6 mice, there was
around 49% reduction in neutrophils (p = 0.05) and
around 83% reduction in monocytes (p = 0.003) in the
blood of the ZOL-treated cohort relative to the control
cohort on day 5 (Fig. 1g, Table 2). Platelets were increased
compared to control at 3, 5 and 10 days after ZOL
Ubellacker et al. Breast Cancer Research  (2017) 19:23 Page 7 of 15
administration, with approximately 49% elevation ob-
served at the 5-day time point (p = 0.01) (Fig. 1g, Table 2).
Moreover, on day 5 there were significant reductions in the
numbers of eosinophils (p = 0.03) and basophils (p = 0.01)
in the ZOL-treated mice (Additional file 5: Figure S3b).
In nude mice, we observed a trend toward reduced
numbers of circulating neutrophils and monocytes with
ZOL treatment relative to vehicle control, although
these numbers were not statistically significant (Fig. 1g,
Table 2). There were also no statistically significant dif-
ferences in the numbers of other blood cell populations
between cohorts at these time points in the nude mice
(Table 2, Additional file 5: Figure S3a).
Taken together with the bone marrow analysis, these
results indicate that reductions in peripheral neutrophils
and monocytes were accompanied by an increase in their
progenitor cells in the bone marrow after administration of
a single, clinically relevant dose of ZOL. In the C57BL/6
mice, the increase in peripheral blood platelets observed
5 days after ZOL treatment preceded the increase in MEPs
observed in the bone marrow, which was observed 15 days
after ZOL treatment. Additionally, although we observed
decreases in the LBP and increases in the CLP populations
in the bone marrow of C57BL/6 mice 5 days after ZOL
treatment, there was not a corresponding change in the
number of lymphocytes in the peripheral blood observed
at this same time point.
Zoledronic acid induces changes to extracellular matrix
and bone cell number and activity
As HSC maintenance and hematopoiesis are tightly
regulated by cells in the endosteal niche, in particular
osteoblasts and osteoclasts, we endeavored to deter-
mine whether the ZOL-induced changes in hematopoietic
cell populations occurred in conjunction with the well-
established effects on these particular bone cells. We
therefore analyzed osteoclast and osteoblast parameters
in the cohorts of nude mice at the time points at which
we had analyzed hematopoietic stem cell populations.
As expected, ZOL caused a significant reduction in
osteoclast activity, as measured by N-telopeptide of type
1 collagen (NTX) plasma concentrations, at both 3 and
5 days after treatment, with levels returning to baseline
by day 10 (day 3: p < 0.0001, day 5: p = 0.0005, day 10:
p > 0.999; Fig. 2a). The decrease in osteoclast activity ob-
served at day 3 was accompanied by an 11.7-fold reduc-
tion in the number of osteoclasts lining trabecular bone
surfaces of the ZOL-treated cohort relative to the
control-treated cohort (p < 0.0001; Fig. 2b, c).
Although the long-term therapeutic effects of bispho-
sphonates are thought to be a consequence of direct in-
hibition of osteoclast-mediated bone resorption, there is
increasing evidence that these drugs also affect osteoblasts,
due to the tight coupling of osteoclast and osteoblast activ-
ity [30, 31]. We observed a transient but significant reduc-
tion in plasma procollagen I N-terminal propeptide (PINP)
(a measure of osteoblast activity) 3 and 5 days after ZOL
administration, after which it was not significantly different
relative to the control cohort (day 3: p < 0.0001, day 5:
p < 0.0001, day 10: p = 0.4, Fig. 2d). Concomitant with
these findings, the number of osteoblasts lining tra-
becular bone surfaces was reduced 3.4-fold relative to
control (p = 0.007, Fig. 2e, f ).
To establish whether these changes in bone cell number
and activity manifested in alterations to bone structure,
we analyzed trabecular bone volume 3 days after ZOL
administration. As expected, no significant alterations
in trabecular bone volume or number were observed at
this early time point (Fig. 2g-i). However, as measured
by proteoglycan staining, we observed increased extra-
cellular matrix deposition in the metaphysis 3 days after
treatment (1.3-fold increase relative to control, p = 0.02)
with a further increase 8 days after ZOL treatment (1.5-fold
increase relative to control, p = 0.001, Fig. 2j, k). Although
gross total bone density had not yet been measurably af-
fected at these relatively early time points, increases in
extracellular matrix deposition in the metaphysis in this
study was consistent with our previous finding that ZOL
increases trabecular bone extracellular matrix deposition
and that increases in bone volume are not observed until
10 days following treatment [21].
These results established that a single dose of ZOL
decreases the number and activity of osteoblasts and
osteoclasts within a few days of administration, after which
activity returns to baseline. Moreover, although gross
changes in bone density were not apparent, significant
Table 2 ZOL-induced modifications to peripheral blood cell counts over time
Control Three days post ZOL Five days post ZOL Ten days post ZOL
Nude Monocytes 0.37 ± 0.10 0.21 ± 0.09 0.27 ± 0.11 0.45 ± 0.11
Neutrophils 2.78 ± 0.46 1.73 ± 0.48 1.86 ± 0.18 2.28 ± 0.65
C57BL/6 Monocytes 0.82 ± 0.20 0.28 ± 0.12* 0.14 ± 0.04* 0.62 ± 0.14
Neutrophils 1.56 ± 0.16 0.98 ± 0.16* 0.79 ± 0.33* 1.41 ± 0.29
Platelets 438.6 ± 32.10 477.0 ± 87.66 653.3 ± 68.50* 512.2 ± 64.50
Average numbers of indicated peripheral blood cells (K/μL ± SEM) from nude and C57BL/6 mice as determined by HEMAVET® at the indicated time points after
control treatment or one 100-μg/kg dose of zoledronic acid (ZOL); n = 4–5 mice per group; *p ≤ 0.05
Ubellacker et al. Breast Cancer Research  (2017) 19:23 Page 8 of 15
changes to the bone extracellular matrix had begun to
manifest. The kinetics of these changes to bone mirrored
those with which alterations to hematopoietic progenitors
(described above) had occurred in the wake of ZOL
treatment.
Effects of zoledronic acid on cells in the vascular niche
Proliferative HSCs are reported to reside in peri-vascular
niches within the bone [32, 33]. Moreover, it has been sug-
gested that ZOL has anti-angiogenic activity in vitro and
reduces circulating pro-angiogenic vascular endothelial
Fig. 2 Effects of zoledronic acid (ZOL) on osteoclasts, osteoblasts and bone structure. a Relative osteoclast activity in nude mice determined by
N-telopeptide of type 1 collagen (NTX) plasma levels at indicated time points after ZOL treatment (n = 4–5 per group); day (d) 3 ****p < 0.0001,
**d5 p = 0.0005, d10 p > 0.999. b Osteoclast number/mm trabecular bone surface (n = 4 per group); ****p < 0.0001. c Representative sections of
tartrate-resistant acid phosphatase-stained tibiae, with an H&E counterstain, 3 days after ZOL or control (Ctl) treatment in nude mice. Osteoclasts stain
bright pink and are indicated by asterisks, Tb trabecular bone, scale bar 100 μm. d Relative osteoblast activity as measured by plasma procollagen I N-
terminal propeptide (PINP) at indicated time points after ZOL treatment (n = 4–5/group); d3 ****p < 0.0001, d5 ****p < 0.0001, d10 p = 0.4. e Osteoblast
number/mm trabecular bone surface (n = 4/group); **p = 0.007. f Representative H&E-stained section of tibiae from Ctl and ZOL-treated mice; arrows
indicate osteoblasts, Tb trabecular bone, Bm bone marrow, scale bar 100 μm. Trabecular bone volume (bone volume/tissue volume, BV/TV in %) (g)
and trabecular number (Tb.N. in mm-1) (h) of nude mouse femora 3 days after treatment (n = 3 for Ctl, n = 4 for ZOL). i Representative micro-
computed CT cross-sections of right femora from Ctl or ZOL treated mice 3 days after treatment. k Average area (mm2) occupied by extracellular
matrix in the metaphysis of nude mice at indicated time points after treatment (n = 3–4 mice/group); d3 *p = 0.02, d8 **p = 0.001. j Toluidine blue-
stained sections of tibiae of nude mice 3 or 8 days after treatment with Ctl or one 100-ug/kg dose of ZOL. Dark purple stain shows bone proteoglycan
(mastocytes, cartilage), light blue stain shows cell nuclei and calcified bone. Scale bar 100 μm
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growth factor (VEGF) in patients with cancer [34–37].
Based on these findings, and on a recent report that HSC
maintenance is regulated by specific bone marrow blood
vessel types [23], we investigated the effects of ZOL on
the bone microvasculature. To do so, we stained bone tis-
sue sections from ZOL and control treated mice for the
endothelial cell marker endomucin, which is expressed by
the vessels in both the metaphysis and diaphysis [23].
In the control cohort, we observed a distinct organization
of endomucin-positive microvasculature, with elongated,
branched tubular vessels occupying the metaphysis and a
more sinusoidal patterning in the diaphysis, as expected.
Although no quantitative difference was observed in the
number of vessels and average length of vessels (Additional
file 6: Figure S4b), the endomucin-positive vasculature of
ZOL-treated animals appeared to comprise shorter,
discontinuous vessels with a deficit of sinusoidal pat-
terning in the diaphysis and an apparent elongation of
the branched zone within the metaphysis (Fig. 3a-f,
Additional file 6: Figure S4a).
Fig. 3 Effects of a single dose of zoledronic acid (ZOL) on bone marrow vasculature. a-d Bone marrow vasculature was visualized 3 days after
control (Ctl) or ZOL treatment using immunofluorescence staining against the vascular endothelial cell marker endomucin (green) on 30-μm-thick
sections of gelatin-embedded tibiae: 8 × 8 tile scans captured with × 20 objective using the Nikon Eclipse Ti, NIS-Elements-software Version 4.30,
CFI Plan Fluor 20x MI (NA 0.75); scale bars 250 μm, arrows indicate branched vasculature, dashed lines represent growth plate demarcation, Ep epiphysis,
Met metaphysis, Dia diaphysis. e-f Z-stacks with a depth of 20 μm of the metaphyseal vasculature (e) and confocal images of the diaphyseal bone marrow
vasculature (f), acquired with the Nikon A1 confocal microscope, NIS-Elements-software Version 4.30, CFI Plan Fluor 20x MI (NA 0.75), Endomucin-positive
vascular endothelial cells (green; Alexa555), nuclei (blue; 4',6-diamidino-2-phenylindole (DAPI)); scale bars 100 μm; n= 3/group. Phase-contrast image (right) is
a toluidine blue stain of a nude mouse tibia to indicate the regions of imaging for the vasculature stains. g Average mouse plasma vascular endothelial
growth factor (VEGF) concentration (pg/mL) 3 days after a single dose of ZOL or Ctl treatment (n= 4 for Ctl, n= 3 for ZOL). ns not significant
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Using a second endothelial cell-surface marker, CD31,
which is expressed by the vessels in the metaphysis but is
absent in the diaphysis [23], we observed no overt differ-
ences in organization and structure of the CD31+ bone
marrow vasculature (Additional file 6: Figure S4a) in the
ZOL-treated cohort when compared to control; however,
the zone occupied by columnar vessels appeared to be ex-
tended, in agreement with the endomucin staining (Fig. 3e).
VEGF plasma levels were not affected 3 days after a single
dose of ZOL or control (p = 0.3, control: 266.2 ± 8.80 pg/
mL vs ZOL: 251.7 ± 7.92 pg/mL, Fig. 3g), indicating that
ZOL did not change VEGF plasma levels at this time point.
Although not easily quantifiable, our observations
support the notion that a single dose of ZOL modifies
the organization of the bone microvasculature in areas
known to comprise HSC niches and thus could, at least
in part, account for the expansion in HSCs that we ob-
served 3 days after ZOL administration. Whether these
ZOL-induced modulations to the microvasculature have
significant effects on hematopoiesis will be the subject of
future studies.
Effect of zoledronic acid-treated bone marrow cells on
breast tumor outgrowth
In recent clinical trials, adjuvant ZOL has been correlated
with reduced breast cancer recurrence, although the pre-
cise mechanism(s) of action for this protective effect re-
mains unknown [25]. Given that hematopoietic cells play
an important role in breast cancer progression [38, 39]
and that our findings demonstrated that ZOL has pro-
found effects on hematopoietic stem and progenitor cells,
we wished to determine whether the ZOL-induced alter-
ations in hematopoiesis have an effect on breast tumor
outgrowth. We based our modeling on the notion that the
outgrowth of disseminated cancer cells encountering a
bone marrow environment that had been modified by
ZOL could be profoundly affected by those ZOL-induced
changes to hematopoietic cells that we had observed.
To exclusively test the effects of ZOL-modified bone
marrow in the absence of overt bone disease, we com-
pared the ability of BMCs isolated from control-treated
and ZOL-treated animals to modulate tumor cell growth
using our previously reported BMC functional assay [40]
(Fig. 4a). To do so, BMCs were isolated from mice at
selected time points after control or ZOL treatment and
admixed with MDA-MB-231 bone-tropic (BO2F11)
human breast tumor cells in a ratio of 3:1. The admix-
tures were immediately injected subcutaneously into
recipient cohorts of nude mice and tumor incidence
and progression were assessed over a period of 14 days
(Fig. 4a). In all cases, we confirmed that the vast majority of
cells in the BMC preparations were CD45+ hematopoietic
cells, with <0.005–0.02% of the cells being CD45-negative
(data not shown).
We first started with BMCs harvested at those time
points at which maximal effects on hematopoiesis were
observed, namely, 3 days in nude mice and 5 days in
C57BL/6 mice. BMCs prepared from the control cohort
of nude donor mice 3 days after vehicle treatment had
no effect on tumor growth; the incidence of tumor
formation was approximately 83% in the cohort of
mice that had received these admixtures and in a cohort
of mice that had been injected with tumor cells only
(i.e., without any admixed BMCs) (Fig. 4b, c). In striking
contrast, BMCs prepared from nude mice 3 days after
ZOL treatment significantly inhibited tumor outgrowth;
only 50% of the injected admixtures formed tumors
(Fig. 4b). Similarly, tumor incidence was only approxi-
mately 17% in the mice that had received donor BMCs
harvested from C57BL/6 mice 5 days after ZOL treatment
while tumors formed in approximately 83% of the mice
that had received control BMCs (Fig. 4b). These results
established that ZOL generates tumor-suppressive bone
marrow but did not reveal whether the changes we had
observed in hematopoiesis were correlated with the in-
hibitory function of the bone marrow.
We reasoned that if ZOL-induced changes to
hematopoiesis could define the tumor-inhibitory bone
marrow, then BMCs isolated from control-treated and
ZOL-treated mice at time points when HSC and HPC
counts had returned to baseline (by 10 days in nude
mice and 15 days in C57BL/6 mice) should no longer
have tumor suppressive capacity. Interestingly, however,
BMCs isolated from ZOL-treated donor mice at these
later time points after treatment also had tumor-inhibitory
function. Specifically, BMCs harvested from nude donor
mice 10 days after ZOL treatment inhibited the outgrowth
of MDA-MB-231 bone-tropic tumor cells (approximately
12% incidence) as compared to control-treated donor
bone marrow (approximately 88% incidence) (Fig. 4b, c).
Likewise, donor BMCs harvested from C57BL/6 mice
15 days after ZOL treatment resulted in decreased inci-
dence of tumor formation (approximately 50%) relative
to the control-treated donor cohort (100%) (Fig. 4b).
Furthermore, in those tumors that did form, 5-day
ZOL-treated BMCs in the nude mice reduced tumor
growth kinetics compared to control-treated bone marrow
cells (Additional file 7: Figure S5a) and 10 day ZOL-
treated BMCs in the nude mice and 5 day ZOL-treated
BMCs in the C57BL/6 mice reduced tumor size compared
to control-treated bone marrow cells (Fig. 4b and
Additional file 7: Figure S5b).
To rule out the possibility that tumor growth inhibition
was the consequence of some residual drug that may have
been retained in the donor bone marrow and introduced
during the admixing process, we tested whether the tumor
cells were susceptible to ZOL treatment. First, MDA-
MB-231 BO2F11 cells were treated in vitro with a dose
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Fig. 4 Zoledronic acid (ZOL) generates tumor-suppressive bone marrow cells. a Experimental design to test bone marrow tumor support function.
Bone marrow cells (BMCs) were harvested from control (Ctl)-treated or ZOL-treated donor mice 3 and 10 days (nude) or 5 and 15 days (C57Bl/6)
after treatment (n = 3 donor mice/cohort): 7.5 × 105 BMCs were directly admixed with 2.5 × 105 luciferase + MDA-MB-231 BO2F11 bone tropic
human breast cancer cells and admixtures immediately injected subcutaneously into cohorts of recipient nude mice (n = 3–6 recipient mice per
cohort with bilateral subcutaneous injections; b and c are representative images of one of three biological replications). Tumor growth was monitored
over a 14-day experimental time course. b Average radiance signal at each injection site per cohort at experimental endpoint (day (d)14) resulting from
admixtures of MDA-MB-231 BO2F11 tumor cells with BMCs from indicated Ctl-treated or ZOL-treated donor nude mice; *p< 0.05. Table indicates incidence
of tumor formation resulting from admixtures of breast tumor cells with BMCs from indicated donor mice. c Representative In vivo imaging system images
of luciferase +MDA-MB-231 BO2F11 tumors resulting from admixtures with BMCs from Ctl-treated or ZOL-treated donor nude mice (10 days after treatment
of donor mice). Imaging was acquired at the 14-day experimental end point. d Nude mice were treated with 100 μL of vehicle or 100 μg/kg ZOL; 3 days later,
mice were injected subcutaneously with 2.5 × 105 MDA-MB-231 BO2F11 and tumor growth was monitored over a 14-day time period. Aver-
age tumor volume (mm3) for indicated cohorts is shown; n.s. not statistically significant. e Nude mice were injected orthotopically with MDA-MB-231 bone-
tropic cells and tumors grew for 30 days before mice were given one dose of Ctl treatment or ZOL (100 μg/kg). BMCs were harvested 3 days
after Ctl or ZOL administration and Lin-Sca1+cKit+(LSKs) were analyzed by flow cytometry, *p < 0.05
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comparable to the dose used in vivo and no statistically
significant differences were observed in the ZOL-treated
cells compared to the control-treated cells in the cell pro-
liferation growth assays (Additional file 7: Figure S5c).
Second, to determine the likelihood that ZOL affected
tumor cells in vivo, mice were administered one dose of
ZOL 3 days prior to subcutaneous injection with MDA-
MB-231 bone-tropic cells, and then re-dosed with ZOL
every 5 days. Tumor growth was monitored over 14 days.
There were no statistically significant differences in total
tumor burden at the experimental end point in the
ZOL-treated cohorts compared to the control cohorts
(Fig. 4d), indicating that ZOL does not directly inhibit
growth of these tumor cells, consistent with earlier re-
ports [41].
As mammary tumors may also impact hematopoiesis, we
wished to determine if the impact of ZOL on hematopoiesis
occurred in the presence of a primary mammary tumor.
We injected MDA-MB-231 bone-tropic cells orthotopically
and after 30 days of tumor growth, we treated the mice
with control or ZOL for 3 days before assessing the bone
marrow by flow cytometry. Consistent with our earlier
observations (Fig. 1) we observed expansion of the LSK
compartment with ZOL, even in the presence of a primary
mammary tumor (Fig. 4e).
Taken together, our findings established that ZOL
treatment generates tumor-suppressive bone marrow
cells. Moreover, these findings indicated that the
tumor-suppressive action of ZOL is longer-lasting than
the transient alterations to bone and hematopoietic cell
numbers.
Discussion
The bisphosphonate ZOL is increasingly being investigated
in the adjuvant and neoadjuvant settings for reducing
breast cancer recurrence in bone [2, 42–46]. A number of
theories have been proposed to explain the protective effect
of ZOL against breast cancer recurrence [47–49]. Our
novel results provide an alternative explanation — that
administration of a single, clinically relevant dose of
ZOL is sufficient to generate bone marrow cells capable
of directly suppressing breast cancer tumor growth.
Our findings have implications for breast tumors that
metastasize to bone by suggesting that ZOL renders the
bone marrow inhospitable for disseminated tumor cells.
Indeed, in a clinical study of patients with breast cancer,
ZOL significantly reduced disseminated tumor cells in
the bone marrow [50]. Given that bone marrow-derived
cells (BMDCs) also play a critical role in supporting
primary tumors and extra-skeletal metastases [4], our re-
sults serve as a prerequisite for understanding how
BMDCs within the tumor microenvironment might be
affected by adjuvant ZOL. This theory is supported by
certain preclinical studies reporting that ZOL decreases
recruitment of BMDCs, such as tumor-infiltrating
immune cells and tumor-associated macrophages, to
peripheral tumor sites [34, 35, 51].
Previous reports from our laboratory have repeatedly
demonstrated that gene expression changes that result
in secretion of various cytokines, chemokines and
growth factors, and not changes in BMC numbers, con-
fer tumor-modulating activities to bone marrow cells
[52, 53]. Likewise, published qPCR array studies of nude
mouse BMCs a week after treatment demonstrate that
ZOL reduces expression of a range of genes, including
known regulators of the endosteal stem cell niches and
of hematopoietic and vascular progenitor cell mobilization
[54]. Such changes in gene expression could help to define
ZOL-induced tumor-suppressive BMCs. Hence, future
studies will be directed toward understanding gene
expression signatures associated with ZOL-treated BMCs
and determining which of these changes render the BMCs
tumor-suppressive.
Conclusions
Our results indicate that the ability of a single, clinically
relevant dose of ZOL to generate tumor-suppressive bone
marrow persists longer than its effects on hematopoiesis.
In a clinical study of patients with osteoporosis, one dose
of ZOL induced statistically significant increases in bone
mineral density and decreases in bone resorption as late
as 36 months after treatment [55]. Results such as these
lend support to the notion that a less frequent dosing
regimen may sustain the clinical benefits of ZOL while
reducing the potential for the toxicity (specifically,
osteonecrosis of the jaw) that has been associated with
frequent ZOL treatment [55]. Moreover, pre-clinical
studies such as ours suggest possibilities for capitalizing
on the beneficial effects of ZOL on reducing breast
cancer metastasis in the bone, identification of bone
marrow cell biomarkers that predict response to ZOL
and improving responses to existing therapies.
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Additional file 5: Figure S3. Peripheral blood counts represented as
average fold change in nude (a) and C57BL/6 (b) mice 3 and 5 days
after ZOL treatment, respectively (n = 4 − 5/group). c CFU assay of
bone marrow, peripheral blood and spleen 3 days after CTL or ZOL
treatment; n = 5 nude mice/cohort, *p < 0.05. d BrDU-positive HSCs as
a percentage of total HSCs per nude mouse femur at early time
points post ZOL treatment; n.s. not significant; n = 5 mice/cohort, 1
femur per mouse. (PDF 986 kb)
Additional file 6: Figure S4. Effects of a single dose of zoledronic
acid (ZOL) on CD31+ bone marrow vasculature. Treatment effects of
ZOL or control (Ctl) on CD31-positive bone marrow vasculature in the
metaphysis 3 days after ZOL treatment in the nude mice (a) was
visualized using immunofluorescence staining against the vascular
endothelial cell marker CD31 on 30-μm-thick sections of gelatin-
embedded tibiae. Z-stacks with a depth of 20 μm were acquired
using the Nikon A1 confocal microscope, NIS-Elements-software
Version 4.30, CFI Plan Fluor 20x MI (NA 0.75), yellow CD31-positive
vascular endothelial cells (Alexa555), blue nuclei (DAPI), n = 3/group.
b Endomucin-positive vessels (red) were tracked manually using
Aperio ImageScope. Number of vessels and their average length are
shown, n = 3/group. (PDF 3075 kb)
Additional file 7: Figure S5. a Growth kinetics of tumors after
injecting host nude mice subcutaneously with admixtures of MDA-MB-
231 BO2F11 cells with either Matrigel control (green) BMCs from nude
mice 5 days after CTL treatment (red) or BMCs from nude mice 5 days after
ZOL treatment (blue); n= 12 host mice per cohort, one subcutaneous tumor
injection per mouse. Bone marrow obtained from three donor mice per
cohort. b Average radiance signal of palpable tumors that grew at each
injection site per cohort at experimental endpoint (day (d)14) resulting from
admixtures of MDA-MB-231 BO2F11 tumor cells with BMCs from indicated
CTL-treated or ZOL-treated donor nude mice. c MDA-MB-231 BO2F11 cells
were treated in vitro with indicated doses of ZOL: 3 days later cell toxicity
was measured using the CytoTox-Glo Assay. Red arrow indicates ZOL dose
that is comparable to in vivo dose (based on estimate of mouse blood
volume as 8% of total mouse body weight). (PDF 458 kb)
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